menu
    • menu

    Company profile for Amplia Therapeutics

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​ Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading c...
    Amplia Therapeutics Limited (ASX: ATX) is an Australian, publicly-listed, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.​ Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and medicinal chemistry researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.​

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amplia TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 21 90 Collins Street Melbourne VIC 3000
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ampliatx.com/site/content/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amplia-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ampliatx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amplia Partners Next&Bio For FAK And Kras Inhibitor Combo Therapy
    Amplia Partners Next&Bio For FAK And Kras Inhibitor Combo Therapy

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208497/0/en/Amplia-Enters-into-Second-Agreement-with-Korean-Specialist-Drug-Screening-Company-Next-Bio-to-Explore-Combination-Therapy-with-FAK-Inhibitor-and-kRAS-Inhibitors.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Amplia Investor Presentation Reveal Additional Confirmed Response
    Amplia Investor Presentation Reveal Additional Confirmed Response

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Key Narmafotinib Patent Granted In U.S.
    Key Narmafotinib Patent Granted In U.S.

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198906/0/en/Key-Narmafotinib-Patent-Granted-in-the-U-S.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    FDA Fast Track For Narmafotinib In Advance Pancreatic Cancer
    FDA Fast Track For Narmafotinib In Advance Pancreatic Cancer

    19 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer-302253755.html

    PR NEWSWIRE
    19 Sep 2024
    Share Share
    FDA Clearance Of Amplia'S Ind For Pancreatic Cancer Trial In Us
    FDA Clearance Of Amplia'S Ind For Pancreatic Cancer Trial In Us

    17 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-clearance-of-amplias-ind-for-pancreatic-cancer-trial-in-us-302037692.html

    PR NEWSWIRE
    17 Jan 2024
    Share Share
    AMP945 Combined with FOLFIRINOX Enhances Treatment Effects Pancreatic Cancer
    AMP945 Combined with FOLFIRINOX Enhances Treatment Effects Pancreatic Cancer

    29 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amp945-combined-with-folfirinox-enhances-treatment-effects-in-model-of-pancreatic-cancer-301836431.html

    PR NEWSWIRE
    29 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search